Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3'-alkylamino oligodeoxynudeotides, 2'-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids

Biochemical Pharmacology

Volumn 53, Issue 10, 1997, Pages 1465-1476

  Gray, Gary D ^a   Basu, Soumitra ^a,b   Wickstrom, Eric ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2' O methyl oligoribonucleotides; Antisense; Cell uptake; Methylphosphonates; Oligonucleotides; Phosphorothioates; PNA

Indexed keywords

NUCLEASE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGODEOXYRIBONUCLEOSIDE METHYLPHOSPHONATE; OLIGORIBONUCLEOTIDE; PEPTIDE NUCLEIC ACID;

ANIMAL CELL; ARTICLE; CELL IMMORTALIZATION; CELL STRAIN 3T3; CELL STRAIN HL 60; CELL TRANSFORMATION; CELL TRANSPORT; CONTROLLED STUDY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HYBRIDIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030841714     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)82440-9     Document Type: Article

References (54)

1. Crooke ST and Lebleu B (Eds.), Antisense Research and Applications. CRC Press, Boca Raton, FL, 1993.
2. Akhtar S, (Ed.), Delivery Strategies for Antisense Oligonucleotide Therapeutics. CRC Press, Boca Raton, FL, 1995.
3. Agrawal S (Ed.), Antisense Therapeutics. Humana Press, Totowa, NJ, 1996.
4. Miller PS, Reddy MP, Murakami A, Blake KR, Lin SB and Agris CH, Solid-phase syntheses of oligodeoxynucleoside methylphosphonates. Biochemistry 25: 5092-5097, 1986.
5. Inoue H, Hayase Y, Imura A, Iwai S, Miura K and Ohtsuka E, Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides. Nucleic Acids Res 15: 6131-6148, 1987.
6. Stein CA, Subasinghe C, Shinozuka K and Cohen JS, Physiochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 16: 3209-3221, 1988.
7. Egholm M, Buchardt O, Nielsen PE and Berg RH, Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone. J Am Chem Soc 114: 1895-1897, 1992.
8. Milligan JF, Matteucci MD and Martin JC, Current concepts in antisense drug design. J Med Chem 36: 1923-1937, 1993.
9. Cummins LL, Owens SR, Risen LM, Lesnik EA, Freier SM, McGee D, Guinosso CJ and Cook PD, Characterization of fully 2′-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res 23: 2019-2024, 1995.
10. Bennett R, As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells. Antisense Res Dev 3: 235-241, 1993.
11. Shaw J-P, Kent K, Bird J, Fishback J and Froehler B, Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res 19: 747-750, 1991.
12. Zendegui JG, Vasquez KM, Tinsley JH, Kessler DJ and Hogan ME, In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res 20: 307-314, 1992.
13. Eckstein F, Nucleoside phosphorothioates. Annu Rev Biochem 54: 367-402, 1985.
14. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS and Broder S, Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci USA 84: 7706-7710, 1987.
15. Iribarren AM, Sproat BS, Neuner P, Sulston I, Ryder U and Lamond AI, 2′-O-Alkyl oligoribonucleotides as antisense probes. Proc Natl Acad Sci USA 87: 7747-7751, 1990.
16. Sproat BS, Lamond AI, Beijer B, Neuner P and Ryder U, Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res 17: 3373-3386, 1989.
17. Hanvey JC, Peffer NJ, Bisi JE, Thomson SA, Cadilla R, Josey JA, Ricca DJ, Hassman CF, Bonham MA, Au KG, Carter SG, Bruckenstein DA, Boyd AL, Noble SA and Babiss LE, Antisense and antigene properties of peptide nucleic acids. Science 258: 1481-1485, 1992.
18. Nielsen PE, Egholm M, Berg RH and Buchardt O, Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254: 1497-1500, 1992.
19. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV and Vlassov VV, Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86: 6454-6458, 1989.
20. Gao WY, Storm C, Egan W and Cheng YC, Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol 43: 45-50, 1993.
21. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L and Gewirtz AM, Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95: 1814-1823, 1995.
22. Shoji Y, Akhtar S, Periasamy A, Herman B and Juliano RL, Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res 19: 5543-5550, 1991.
23. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H and Krieg AM, Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3: 53-66, 1993.
24. Srivastava SK, Yuasa Y, Reynolds SH and Aaronson SA, Effects of two major activating lesions on the structure and conformation of human ras oncogene products. Proc Natl Acad Sci USA 82: 38-42, 1985.
25. Chang EH, Miller PS, Cushman C, Devadas K, Pirollo KF, T'so POP and Yu ZP, Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 30: 8283-8286, 1991.
26. Pietrzkowski Z, Sell C, Lammers R, Ullrich A and Baserga R, Roles of insulinlike growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells. Mol Cell Biol 12: 3883-3889, 1992.
27. Collins SJ, Ruscetti FW, Gallagher RE and Gallo RC, Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 75: 2458-2462, 1978.
28. Collins S and Groudine M, Amplification of endogenous myc-related DNA sequences in a human myeloid leukemia cell line. Nature 298: 297-302, 1982.
29. Sinha ND, Biernat J, McManus J and Köster H, Polymer support oligonucleotide synthesis XVIII: Use of β-cyanoethyl-N,N-dialkylamino-N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product. Nucleic Acids Res 12: 4539-4557, 1984.
30. Hogrefe RI, Reynolds MA, Vaghefi MM, Young KM, Riley TA, Klem RE and Arnold LJ Jr, An improved method for the synthesis and deprotection of methylphosphonate oligonucleosides. In: Protocols for Oligonucleotides and Analogs: Synthesis and Properties (Ed. Agrawal S), pp. 143-164. Humana Press, Totowa, NJ, 1993.
31. Christensen L, Fitzpatrick R, Gildea B, Petersen KH, Hansen HF, Koch T, Egholm M, Buchardt O, Nielsen PE, Coull J and Berg R, Solid-phase synthesis of peptide nucleic acids. J Peptide Sci 3: 175-183, 1995.
32. Sproat BS, Synthesis of 2′-O-alkyloligoribonucleotides. In: Protocols for Oligonucleotides and Analogs: Synthesis and Properties (Ed. Agrawal S), pp. 115-142. Humana Press, Totowa, NJ, 1993.
33. Sawadogo M and Van Dyke MW, A rapid method for the purification of deprotected oligodeoxynucleotides. Nucleic Acids Res 19: 674, 1991.
34. Bridson PK and Reese CB, A novel method for the methylation of heterocyclic amino groups. Conversion of guanosine into its 2-N-methyl- and 2-N,2-N-dimethyl derivatives. Bioorg Chem 8: 339-349, 1979.
35. Hughes JA, Avrutskaya AV, Brouwer KLR, Wickstrom E and Juliano RL, Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs. Pharm Res 12: 817-824, 1995.
36. Beaucage S, Oligodeoxyribonucleotide synthesis: Phosphoramidite approach. In: Protocols for Oligonucleotides and Analogs: Synthesis and Properties (Ed. Agrawal S), pp. 33-62. Humana Press, Totowa, NJ, 1993.
37. Marti G, Egan W, Noguchi P, Zon G, Matsukura M and Broder S, Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells. Antisense Res Dev 2: 27-39, 1992.
38. Löscher W, Böhme G, Müller F and Pagliusi S, Improved method for isolating synaptosomes from 11 regions of one rat brain: Electron microscopic and biochemical characterization and use in the study of drug effects on nerve terminal γ-aminobutyric acid in vivo. J Neurochem 45: 879-889, 1985.
39. Dewanjee MK, Ghafouripour AK, Hanna M, Subramanian M, Willem L, Kapadvanjwala M, Lopez DM, Serafini AN and Sfakianakis N, Tumor cell killing by Y-90 labeled Bc12 antisense oligodeoxynucleotide probes. Protein Eng 8S: 84, 1995.
40. Kitajima I, Shinohara T, Minor T, Bibbs L, Bilakovics J and Nerenberg M, Human T-cell leukemia virus type I tax transformation is associated with increased uptake of oligodeoxynucleotides in vitro and in vivo. J Biol Chem 267: 25881-25888, 1992.
41. Iversen PL, Crouse D, Zon G and Perry G, Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible. Antisense Res Dev 2: 223-233, 1992.
42. Pirruccello SJ, Perry GA, Bock PJ, Lang MS, Noel SM, Zon G and Iversen PL, HIV-1 rev antisense phosphorothioate oligonucleotide binding to human mononuclear cells is cell type specific and inducible. Antisense Res Dev 4: 285-289, 1994.
43. Daaka Y and Wickstrom E, Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res 5: 267-275, 1990.
44. Orson FM, Thomas DW, McShan WM, Kessler DJ and Hogan ME, Oligonucleotide inhibition of IL2Ra mRNA transcription by promoter region collinear triplex formation in lymphocytes. Nucleic Acids Res 19: 3435-3441, 1991.
45. Leonetti JP, Mechti N, Degols G, Gagnor C and Lebleu B, Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 88: 2702-2706, 1991.
46. Clarenc JP, Lebleu B and Leonetti JP, Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogues. J Biol Chem 286: 3600-3604, 1993.
47. Fisher TL, Terhorst T, Cao X and Wagner RW, Intracellular disposition and metabolism of fluorescently labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res 21: 3857-3865, 1993.
48. Krieg AM, Gmelig-Meyling F, Gourley MF, Kisch WJ, Chrisey LA and Steinberg AD, Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res Dev 1: 161-171, 1991.
49. Howell KE, Devaney E and Gruenberg J, Subcellular fractionation of tissue culture cells. Trends Biochem Sci 14: 44-47, 1989.
50. Iversen PL, Zhu S, Meyer A and Zon G, Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 2: 211-222, 1992.
51. Miller PS, Non-ionic antisense oligonucleotides. In: Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression (Ed. Cohen JS), pp. 79-95. CRC Press, Boca Raton, FL, 1989.
52. Campbell JA, Bacon TA and Wickstrom E, Oligodeoxynucleoside phosphorothioate stability in serum, cerebrospinal fluid, urine, subcellular extracts, and culture media. J Biochem Biophys Methods 20: 259-267, 1990.
53. Tang JY, Temsamani J and Agrawal S, Self-stabilized antisense oligodeoxynucleotide phosphorothioates: Properties and anti-HIV activity. Nucleic Acids Res 21: 2729-2735, 1993.
54. Demidov VV, Potaman VN, Frank-Kamenetskii MD, Egholm M, Buchardt O, Sonnichsen SH and Nielsen PE, Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacd 48: 1310-1313, 1994.